ClinVar provides open access to variant classifications shared from many clinical laboratories.
INTRODUCTION
Since its release in 2012, ClinVar (https://www.ncbi.nlm.nih. Publications assessing the volume of classification differences in ClinVar have produced conflicting findings, often varying by whether annotations such as collection method and review status are accounted for Lincoln et al., 2017; or not accounted for (Balmaña et al., 2016; Gradishar, Johnson, Brown, Mundt, & Manley, 2017) . A comprehensive paper analyzing all ClinVar variants classified by two or more submitters found 81% concordance when including oneand two-step differences between the three major classification levels (pathogenic [P]/likely pathogenic [LP] , variants of uncertain significance [VUS] , and likely benign [LB]/benign [B] ) and 94.1% concordance when limiting to medically significant differences (MSDs; P/LP vs. VUS/LB/B). When including variants that had a majority consensus, meaning at least two thirds of the classifications were in the same group, concordance between submitters increased to 96.7% . The difference between complete concordance (94.1%) and majority consensus (96.7%) indicates that of the variants with MSDs between submitters, a subset reach majority consensus with an outlier classification(s) accounting for the discordance. Additionally, when looking at date ranges of outlier submissions, Yang et al. (2017) found that submissions pre-2014 were significantly more likely to be outliers compared to post-2014, suggesting that older submissions are also a significant factor in discordance rates.
Regardless of the true volume of classification differences, sharing variant classifications facilitates identification of differences and allows data sharers the opportunity to reassess and potentially resolve differences. A recent study comparing BRCA1 and BRCA2 variant classifications across 11 clinical laboratories sharing through the Canadian Open Genetics Repository found an initial 26.7% classification discordance rate (Lebo et al., 2018) . Upon sharing and comparing classifications, the discordance rate decreased to 14.2%, with the majority of discrepancies resolved by new evidence (44.8%) or revised classification criteria (35.3%). Another study comparing variant interpretations across five hypertrophic cardiomyopathy centers participating in the Sarcomeric Human Cardiomyopathy Registry found an initial 20.5% discordance rate (Furqan et al., 2017) . Reassessment and data sharing prompted by the registry reduced the discordance rate to 10.7%, with 35% resolved by review of new data and 13% resolved by reassessment with current classification practices. Both examples illustrate the point that sharing variant classifications and subsequent notification of classification differences can serve as a prompt for reassessment that might not occur within a single laboratory given the rarity of Mendelian disease variants.
In a pilot project from ClinGen's Sequence Variant Inter-Laboratory Discrepancy Resolution group, four clinical laboratories (Ambry Genetics, GeneDx, Partners HealthCare Laboratory for Molecular Medicine, and University of Chicago Genetic Services Laboratories) collaborated to investigate the ability of laboratories to resolve differences through reassessment and data sharing and to identify trends that could educate future plans for discrepancy resolution between all ClinVar submitters (Harrison et al., 2017) . Laboratories resolved 87.2% of discordant variants reviewed (211/242), of which 36% were resolved by application of updated classification criteria and 17% were resolved because the reinterpretation had already been completed internally but had not yet been updated in ClinVar.
Although the pilot project was successful in both resolving classification differences and identifying trends in classification differences between clinical laboratories, the pilot only included four clinical laboratories and required a major time commitment (an estimated 1-2 hr per variant per laboratory) as participating laboratories were encouraged to reassess all identified variants with classification differences.
To improve efficiency and tackle the variants most likely to be resolved without exchange of detailed datasets, our working group began a second phase of variant classification resolution, which included two modifications in scope compared to the pilot project. First, this working group expanded its membership from 4 to 41 clinical laboratories to help elevate the review status of more variants in ClinVar from a "criteria provided, conflicting interpretations" status to a "criteria provided, multiple submitters, no conflicts" status, which requires that all submitters have concordant classifications. Second, given the increase in volume due to involvement of more clinical laboratories, we first focused on outlier classifications. As results from the pilot project indicated that ∼53% of variants were resolved by reassessment or a recently completed reclassification not yet shared in ClinVar, this focus on outlier classifications on variants with MSDs in ClinVar was anticipated to resolve a large number of discrepancies while minimizing the total time commitment for all laboratories to participate. Although the classifications achieving majority consensus are not necessarily more accurate, this approach was chosen as an efficient means of identifying classification differences that are more likely to be resolved with limited efforts (only one laboratory reassessing) as well as those due to differences in classification algorithms, changes in available evidence, or outdated data in ClinVar.
MATERIALS AND METHODS

ClinVar data analysis
Our analyses used the ClinVar April 2017 submission_summary file (released April 5, 2017; ftp://ftp.ncbi.nlm.nih.gov/pub/clinvar/ tab_delimited/) to identify all variants in ClinVar with submissions from two or more of the selected 41 clinical laboratories. Using the three major classification levels (P/LP, VUS, and LB/B), classifications for each variant were compared to determine concordance or discordance, and if discordant, the level of discordance was assigned. For variants with greater than two classification terms submitted, the two most discordant terms were used to assign the level of discordance.
For example, a variant with a pathogenic, uncertain significance, and benign classifications would be categorized by the pathogenic versus benign difference. To allow for comparison analyses, the same process, but for all ClinVar submitters, was used to determine concordance/discordance parameters for the entire ClinVar dataset.
To identify outlier classifications in ClinVar, variants with MSDs 
Laboratory data analysis
Each laboratory with at least one outlier classification on a variant with a MSD was sent a custom report (Supporting Information File S1). Laboratories were asked to first determine if the variant had already been reclassified internally but not yet updated in ClinVar, and if not, were asked to reassess the variant with current evidence and methods. If the laboratory's classification was still discordant after reassessment, the laboratory was asked to share the evidence and rationale contributing to the classification. For statistical comparisons, Fisher's exact test was used. A P-value < 0.01 was used as a threshold for statistical significance. Only 2.7% (650 variants) of the 24,445 shared variants had MSDs, which are most likely to impact medical management. The majority of MSDs (90.5%; 588 variants) were P/LP versus VUS differences and only 62 variants of this set (9.5%) had P/LP versus LB/B differences.
RESULTS
Initial ClinVar concordance data
The remaining 12.7% (3118 variants) of all shared variants were VUS versus benign (LB/B) differences, which are less likely to affect medical management, though often lead to differences in counseling and clinical follow-up time.
F I G U R E 1
Comparison of classification concordance and discordance between all ClinVar submitters and the 41 clinical laboratories participating in this study. Only variants with classifications from ≥2 submitters were included from either group. For variants with greater than two classification terms submitted, the two most discordant terms were used to assign the level of discordance. Data from April 2017
Outlier analysis
Six hundred fifty variants with MSDs were further refined to determine which variants had a majority consensus in ClinVar (Figure 2 ). As the majority consensus determination requires more than two-thirds consensus, only MSDs with three of more submitters were analyzed (244 variants). Of the 244 variants, 87.3% (213 variants) had a majority consensus at the time in ClinVar. Due to low volume of each, variants that either (a) had a LB/B majority consensus (n = 12) or (b) had both VUS and LB/B classifications when combined resulted in a nonpathogenic majority consensus (n = 12; for example, a variant with five submitters: one pathogenic, three VUS, and one benign) were both designated as "VUS/B" majority consensus. Of the 213 variants that had a majority consensus, 47.9% (102 variants) were a pathogenic majority consensus with VUS outlier(s), 40.8% (87 variants) were a VUS majority consensus with P/LP outlier(s), and 11.3% (24 variants) were a VUS/B consensus with P/LP outlier(s) (Figure 2 
Laboratory reassessment
Although the initial analysis for concordance included classifications from 41 clinical laboratory ClinVar submitters, only 17 laboratories had one or more outlier classifications (Supporting Information Table   S1 ). Overall, 17 laboratories with one or more outlier classifications had not yet been updated in ClinVar (Figure 4 ; Supporting Information Table S2 ).
Comparing outlier scenarios, there was no statistically significant differences in the resolution rate between any of the three scenarios: majority consensus P/LP outlier VUS variants (58.6%; 58/99 variants), majority consensus VUS outlier P/LP variants (61.4%; 51/83 F I G U R E 2 Flowchart and outcome of variant resolution efforts. Classifications submitted to ClinVar from 41 clinical laboratories were first compared to identify medically significant differences (MSDs; 650 variants). Next, to identify MSDs that reach a majority consensus with an outlier classification, only MSDs with ≥3 submitters were analyzed (244 variants), of which 87.3% (213 variants) had a majority consensus in ClinVar. A further breakdown of the 213 variants into three majority consensus/outlier scenarios is provided. Clinical laboratories with outlier classifications were each sent a report and asked to reassess those variants. Clinical laboratories returned results from 204 variants, of which 62.3% (127 variants) were reclassified by the outlier laboratory resulting in classification resolution. MC, majority consensus F I G U R E 3 Distribution of interpretation differences and resolution outcome per disease area. Distribution of outlier scenarios within each disease area before ("initial") and after ("outcome") reassessment, including proportion resolved. Initial and outcome variant counts differ due to incomplete reassessments by outlier submitters. MC, majority consensus variants), and majority consensus VUS/B outlier P/LP variants (81.8%; 18/22 variants). However, if focusing only on resolution of the subset of majority consensus VUS/B outlier P/LP variants that were majority consensus LB/B outlier P/LP variants (100% resolution; 11/11 variants), the differences in resolution compared to majority consensus P/LP outlier VUS variants (58.6%; 58/99 variants) were statistically significant (P = 0.0064). Differences in the resolution rate between majority consensus LB/B outlier P/LP variants (100% resolution; 11/11 variants) and majority consensus VUS outlier P/LP variants (61.4%; 51/83 variants) approached but did not meet statistical significance (P = 0.0140). Additionally, there were no significant differences in the resolution rates of outlier types by disease area (Figure 3) . For the 77 unresolved variants, evidence and notes returned by the outlier laboratory were analyzed to determine trends for persistent differences. Overall, differences in classification for variants indicated as risk or low-penetrant pathogenic accounted for 7.8% of unresolved variants (six variants total; four majority consensus VUS/B with P/LP outlier variants; two majority consensus VUS with P/LP outlier variants). Additionally, differences in classifying allelic or haplotype variants accounted for 5.2% of unresolved variants (four variants total; three majority consensus P/LP with VUS outlier variants; one majority consensus VUS with P/LP outlier variant).
Lastly, to assess the impact of outlier notification, we compared resolution rates of variants prompted for reassessment by this study to the resolution rate for variants not prompted for reassessment. To assemble this comparison group, we identified variants with MSDs that did not reach a majority consensus in April 2017 (437 variants; Figure 2 ) and therefore were not included in any reports to individual laboratories. April 2018 ClinVar data were used to determine whether MSDs remained over the time frame of the study. After 1 year, 24.3% (106) of variants that previously had MSDs, but did not have majority consensus in ClinVar and were not reported to individual laboratories as part of this study, became concordant between clinical laboratories in ClinVar. This is a significantly lower proportion (106/437; P < 0.0001) than variants resolved when individual laboratories were prompted to reassess outlier variants (127/204 variants). However, given that the variants that were not prompted for reassessment also did not have a majority consensus, other factors may be contributing to the lower resolution rates.
DISCUSSION
Clinical laboratory reassessment, prompted by notification of outlier classifications on variants with MSDs in ClinVar, resulted in 62.3% (127 variants) resolution. Importantly, this resolution rate does not include data sharing between laboratories, which in our pilot project impacted 33% of resolved variants. Instead, the goal of this project was to determine if engagement with clinical laboratories submitting to ClinVar and notification of outlier classifications compared to the majority consensus could resolve interpretation differences in a more time-efficient manner than having all laboratories involved in a discrepancy re-evaluate variants from the start. This approach allows us to first resolve classification differences that are simply due to missing certain sources of evidence identified by subsequent submissions, often not available during an earlier assessment, which minimizes the time commitment from participating laboratories. The fact that only 62.3% of variants were resolved by reassessment by the outlier laboratory suggests that laboratories were not reclassifying outlier classifications just to be in concordance with other clinical laboratories.
As participating laboratories were only queried regarding timing of reclassifications (prior to this study versus the result of a reassessment prompted by this study) and not the rationale for reclassifications, a limitation of this study is that we are unable to determine what evidence types and classification algorithm changes are most likely to impact reclassifications, factors evaluated in our prior study (Harrison et al., 2017) . However, we can determine that assessment date is a major reclassification factor as we identified a significantly higher resolution rate when the outlier's previous interpretation was from 2014 or older (74.6%; 56/75 variants) compared to the resolution rate when the outlier's previous interpretation was from 2015 or newer (51.5%; 68/132 variants; P = 0.0016). Although new evidence including the emergence of large-scale population databases such as ExAC (Lek et al., 2016) and gnomAD presumably impacted the higher resolution rate in variants interpreted before 2015, this also correlates with release of the 2015 ACMG and AMP guidelines for variant interpretation (Richards et al. 2015) , which may also play a significant role in resolution efforts by promoting consistent interpretations among laboratories. This finding is supported by a 2017 survey of 65 laboratories, which found that 97% of laboratories use the evidence criteria described in the 2015 ACMG/AMP guidelines for variant classification (Niehaus_ACMGAbstract# 258).
General policies for variant reassessment vary by clinical laboratory. However, most laboratories reassess variants when they are observed in an additional case, at the request of providers, and/or with the release of new interpretation guidelines. In our study, 35.4% (45 variants) of resolved variants resulted from internal reclassifications that had not yet been updated in ClinVar, which suggests that for a subset of discrepancies, routine reassessment based on continued observation of the variant will resolve differences. The remaining 64.6% (82 variants) of resolved outlier variants were due to laboratory reassessment prompted by this study. Although a subset of these discrepancies could be resolved over time with additional observations and routine reassessment, many variants identified in Mendelian disease testing are extremely rare, as evidenced by a study showing that 77% of pathogenic, likely pathogenic, and uncertain significance variants from a single laboratory were only observed once (Rehm et al., 2015) . Therefore, sharing variant interpretations in ClinVar is critical as an additional ongoing quality assurance measure for laboratory reassessment of rare variants.
Because only the outlier laboratory was prompted to reassess each variant and share their classification rationale and evidence, comparisons to the rationale and evidence used by other laboratories are not available; however, based on data from the outlier laboratories, we can identify variant characteristics likely to result in discordance.
For example, these data highlight the need for community consensus around nonstandard variant classification terminology. Indeed, our variants with P versus VUS/B classification differences were unresolved after outlier reassessment because the outlier submitter internally classifies the variant as a risk allele but submitted the variant to ClinVar as benign for a Mendelian disorder. Additionally, of the 18 majority consensus VUS/B outlier P/LP variants resolved, three variants were resolved by a submitter changing their classification to "risk" in ClinVar, as nonstandard classification terms do not factor into concordance in ClinVar. This issue with terminology regarding risk alleles was also noted by Yang et al. (2017) , who found that variants that deemed to be "low penetrance" or "risk" by text analysis were less likely to be concordant (49.2%) than observed across all ClinVar data (89.3%), indicating that risk and/or low-penetrance pathogenic variants contribute a significantly disproportionate fraction of discordance in ClinVar. Comparing interpretations across five clinical laboratories, Garber et al. (2016) found only two of 293 variants had pathogenic versus benign interpretation differences, and both were variants that are not disease causing but impact newborn screening results and thus have clinical relevance for the tested individual and provider (Garber et al., 2016) . These examples suggest that although P versus B discrepancies are rare (0.3% of all variants classified by ≥2 of the 41 submitters in this study; 62/24,445 variants) and critical to resolve, a subset of these discrepancies may be due to nonstandard variant terminology issues. Thus, the community and ClinVar would benefit from guidance regarding terminology and criteria needed to interpret variants in the spectrum of risk/susceptibility or reduced penetrance as well as clinically relevant variants that are not disease causing.
Results for this study also suggest that differences in how laboratories store and submit allelic variants (such as haplotype and cis/trans variants) to ClinVar can be a cause of classification discordance. Of the total resolved variants (127), two variants that had majority consensus P/LP with VUS outlier were resolved by the outlier laboratory decid- Variants prompted for resolution in our study had significantly higher resolution rates compared to variants with MSDs that did not reach a majority consensus, and thus were not prompted for reassessment by this study (24.3%; 106/437). We believe that notification of outlier classifications is a successful approach to scaling resolution efforts between clinical laboratories, while minimizing the time commitment from all laboratories. However, given that 67.2% (437/650 variants) of all MSDs between laboratories did not have a majority consensus initially, the outlier approach is not sufficient to address all discordant classifications.
In the next phase of discrepancy resolution, in addition to sharing internal data on unresolved outlier variants, we will also include resolution efforts on MSDs with only two clinical submitters, as these variants accounted for 92.9% (406/437 variants) of all MSDs that did not have a majority consensus. Discrepancies between only two clinical laboratory submitters will be prioritized by identifying pairs of clinical laboratories with a high rate of discordance. By working one-onone, a pair of laboratories may identify trends in classification algorithm differences between the labs that could facilitate continued resolution and prevent future discrepancies (Garber et al., 2016) . In addition, given that date of evaluation was a statistically significant factor in resolution rates, we will request that the laboratory with the older classification evaluate the variant first to minimize the time required by each laboratory. Finally, we will also ask the small number of laboratories that have not publicly shared their evidence for variant classification to reassess their variants first.
The 41 submitters selected for this study do not represent all clinical laboratories sharing data in ClinVar. Future rounds of variant resolution using the majority consensus and outlier approaches will include data from all ClinVar submitters that designate submissions with "clinical testing" as the collection method (227 submitters; April 2018). This task will be facilitated by recent automation of the report generation process, which means that comprehensive reports including all differences, not just outliers, can be sent to clinical laboratories on a routine basis. Laboratories may also identify discrepant classifica- conflicting classification, such as by submitter or by level of conflict (Butler et al 2018; Henrie et al., 2018) . 
